10-Q: BioLife Solutions Reports Strong Q3 Revenue Growth, Strategic Focus

BioLife Solutions posted a 31% revenue increase in Q3 2025, returning to net income while strategically divesting non-core assets and acquiring new cryopreservation technology.

Summary

• Total revenue from continuing operations increased by 31% to $28.1 million for the three months ended September 30, 2025, compared to $21.4 million in the same period of 2024.
• Product revenue from cell processing grew 33% to $25.3 million in Q3 2025, driven by increased customer demand for commercially approved therapies and $1.3 million in early Q4 shipments.
• Product revenue from evo and Thaw products increased 8% to $1.0 million in Q3 2025, primarily due to pricing increases on Thaw products.
• Rental revenue from evo and Thaw systems rose 24% to $1.8 million in Q3 2025, mainly due to increased pricing on rental agreements.
• The company reported net income from continuing operations of $621 thousand in Q3 2025, a significant improvement from a net loss of $471 thousand in Q3 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, significantly increased to $15.2 million, up from $6.8 million in the prior year.
• Acquired the remaining 90% of PanTHERA CryoSolutions Inc. on April 4, 2025, for $16.8 million, gaining patented Ice Recrystallization Inhibitor (IRI) GEN 2 cryopreservation technology.
• Expensed $15.5 million as in-process research and development (IPR&D) related to the PanTHERA acquisition, as the technology did not meet alternative future use criteria.
• Divested SAVSU Cleo Technologies, LLC on October 6, 2025, for an aggregate purchase price of $25.5 million, a subsequent event to the reporting period.
• Remediated a material weakness in internal control over financial reporting related to stock-based award inputs, identified as of December 31, 2024.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth in its continuing operations and returned to net income in the most recent quarter, indicating positive momentum in its core business. Strategic divestitures are streamlining the portfolio, and the PanTHERA acquisition adds promising technology. While a net loss persists for the nine-month period due to a significant IPR&D expense, and there are ongoing legal and tax liabilities, the improved operating cash flow and stated sufficient liquidity provide a generally positive outlook for the focused entity.

Positives

• Strong revenue growth from continuing operations: 31% increase in Q3 2025 ($28.1 million) and 30% increase in 9M 2025 ($77.4 million) year-over-year.
• Return to net income from continuing operations in Q3 2025 ($621 thousand) compared to a net loss in Q3 2024 ($471 thousand).
• Significant increase in net cash provided by operating activities to $15.2 million for the nine months ended September 30, 2025, up from $6.8 million in the prior year.
• Strategic acquisition of PanTHERA CryoSolutions Inc. and its IRI GEN 2 cryopreservation technology, enhancing core biopreservation capabilities.
• Successful divestiture of SAVSU Cleo Technologies, LLC for $25.5 million post-period, further optimizing the product portfolio towards higher-margin streams.
• Remediation of the previously identified material weakness in internal control over financial reporting during Q1 2025.
• Liquidity position of $98.4 million in cash, cash equivalents, and available-for-sale securities as of September 30, 2025, deemed sufficient for at least the next twelve months.

Negatives

• Reported a net loss from continuing operations of $15.7 million for the nine months ended September 30, 2025, compared to a loss of $9.2 million in the prior year, primarily due to the IPR&D expense.
• Operating loss for the nine months ended September 30, 2025, worsened to $17.9 million from $5.0 million in the prior year, largely due to the $15.5 million IPR&D expense.
• Significant increase in net cash used in investing activities to $72.7 million for the nine months ended September 30, 2025, primarily due to increased purchases of available-for-sale securities and the PanTHERA acquisition.
• Increased operating expenses across cost of revenue, general and administrative, and research and development categories.
• The probability of PanTHERA Sellers achieving earnout targets (up to $7.2 million) was determined to be remote as of September 30, 2025, indicating potential underperformance relative to initial acquisition expectations.
• A full valuation allowance of $56.8 million was recorded against deferred tax assets due to uncertainty regarding the future realizability of U.S. net operating loss carryforwards.

Risks

• Ongoing legal contingencies from the divested Global Cooling business, including a $1.4 million claim and a $4.0 million claim from previous customers, for which the company is required to indemnify Global Cooling.
• An estimated sales tax liability of $3.7 million as of September 30, 2025, for periods 2019 through 2024, due to nexus determinations across various jurisdictions.
• The global business environment continues to be impacted by cost pressure, volatility in global trade policies, tariffs, overall effects of economic uncertainty on customers' purchasing patterns, and high interest rates.
• The company's ability to realize deferred tax assets is dependent upon the generation of future taxable income, which is uncertain, leading to a full valuation allowance.
• Future litigation cannot be predicted with certainty and can have an adverse impact due to defense and settlement costs, and diversion of management resources.

Future Outlook

Management believes current cash, cash equivalents, and other liquid assets, including proceeds from the recent SAVSU divestiture, will be sufficient to meet liquidity needs for at least the next twelve months and the foreseeable future. The company continues to evaluate opportunities for organic growth innovations, partnerships, and acquisitions to maximize the value of its product platforms in the cell and gene therapy market.

Management Comments

• Roderick de Greef, CEO, and Troy Wichterman, CFO, certified that the report fairly presents the financial condition and results of operations.
• Management believes that current cash, cash equivalents, and other liquid assets will be sufficient to meet liquidity needs for at least the next twelve months from the date of the filing and for the foreseeable future.

Industry Context

BioLife Solutions operates within the dynamic and growing cell and gene therapy (CGT) industry, providing critical bioproduction products and services. The company's strategic divestitures of non-core assets (Global Cooling, SciSafe, CBS, and SAVSU) and the acquisition of PanTHERA's advanced cryopreservation technology indicate a focused effort to streamline its portfolio and enhance its position in high-margin, specialized CGT solutions. The reported increase in demand from customers with commercially approved therapies suggests a maturing market for CGT products, benefiting suppliers like BioLife Solutions. The company's focus on biopreservation, cell processing, and thawing devices aligns with key bottlenecks and quality control needs in the CGT workflow.

Corporate Governance

Legal Proceedings

• Two lawsuits filed by previous customers seeking payment for losses allegedly related to commercial freezer products from Global Cooling prior to its divestiture. The company is required to indemnify Global Cooling for these preexisting legal contingencies.
• A loss contingency of $1.4 million was recorded in Q3 2025 for a claim related to Global Cooling, with probable settlement within the next fiscal year.
• A loss contingency of $4.0 million was recorded in Q4 2024 for another claim related to Global Cooling, with probable settlement within the next fiscal year.
• Both product liability claims are subject to insurance recovery, which management believes is probable to be enforceable under the company's insurance policy, covering the entirety of the loss contingencies aside from deductibles.

Stakeholder Impact

• Shareholders: Potential for increased value from strategic focus on higher-margin CGT products and successful integration of PanTHERA technology, offset by short-term losses from IPR&D expense and ongoing legal/tax liabilities. The SAVSU divestiture provides cash proceeds.
• Employees: A reduction in force of 47 employees (11% of full-time workforce) occurred with the Global Cooling divestiture in 2024. New controls implemented for PanTHERA acquisition and convertible promissory note purchase.
• Customers: Increased demand for cell processing products, especially from those with commercially approved therapies, indicates strong customer reliance on BioLife's core offerings. New technologies like PanTHERA's IRI GEN 2 aim to improve product quality and de-risk manufacturing.
• Creditors: The company is in compliance with covenants set forth in its Loan Agreement. Long-term debt balance has decreased, improving the debt profile.
• Regulatory Authorities: Remediation of internal control weaknesses and ongoing evaluation of new tax laws demonstrate commitment to compliance.

Next Steps

• Finalize accounting for the SAVSU divestiture, expected to be presented as discontinued operations in the Annual Report on Form 10-K for the year ended December 31, 2025.
• Continue to evaluate the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its Consolidated Financial Statements.
• Reevaluate the estimated sales tax liability and timing of satisfaction each reporting period.
• Resolve working capital adjustments related to the SciSafe Divestiture.
• Continue to provide certain transition services to SAVSU through December 31, 2025, as per the transition services agreement.
• Continue to provide certain transition services to CBS following the closing of the CBS Divestiture, until expiration of the CBS TSA and related covenants.
• Continue to provide certain transition services to SciSafe for up to six months following the closing of the SciSafe Divestiture, until expiration of the SciSafe TSA and other related covenants.

Key Dates

Recommendation

BioLife Solutions is undergoing a significant strategic transformation, divesting non-core assets and focusing on its high-growth cell and gene therapy segment. The strong revenue growth in continuing operations and improved Q3 net income are positive indicators. However, the substantial IPR&D expense for the PanTHERA acquisition led to a larger nine-month net loss, and the long-term profitability of this investment is yet to be proven. While operational cash flow is strong, the overall cash position has decreased, and there are ongoing legal and tax liabilities. The recent SAVSU divestiture provides a cash infusion, but the company's future performance hinges on the successful integration and commercialization of its refined strategy. Given the mixed financial results (strong revenue vs. 9M loss) and the ongoing strategic shifts, a 'hold' recommendation is appropriate, awaiting clearer signs of sustained profitability and successful execution of its refined strategy.

Keywords

BioLife Solutions, BLFS, Cell and Gene Therapy, CGT, Biopreservation Media, CryoStor, HypoThermosol, Cell Processing, Sexton, ThawSTAR, evo Shipping Containers, PanTHERA CryoSolutions, IRI GEN 2, Cryopreservation Technology, SEC Filing, 10-Q, Financial Results, Acquisition, Divestiture, SAVSU, Operating Income, Cash Flow, Bioproduction